Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIL-TC150 in pediatric Dravet syndrome
NCT02983695Phase 1Completed
- Sponsor
- SickKids
- Start
- Feb 2017
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of T2:C100 in Dravet syndrome, sponsored by SickKids. Primary endpoints: Establishment of tolerability of TIL-TC150 by measuring adverse events and abnormal laboratory values and Establishment of tolerability of TIL-TC150 by pediatric epilepsy side effects questionnaire (PESQ). Started Feb 2017; status: completed.
02
Drugs
T2:C100
03
Conditions
Dravet syndrome
Beyond the preview
Go deeper on NCT02983695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02983695.